Literature DB >> 17710547

Effects of amlodipine, captopril, and bezafibrate on oxidative milieu in rats with fatty liver.

Zvi Ackerman1, Mor Oron-Herman, Talma Rosenthal, Orit Pappo, Gabriela Link, Ben-Ami Sela, Maria Grozovski.   

Abstract

Oxidative stress may initiate significant hepatocyte injury in subjects with fatty liver. We characterized changes in hepatic oxidative anti-oxidative parameters in rats given a fructose-enriched diet (FED) with and without medications to reduce blood pressure or plasma triglycerides. FED rats had an increase in malondialdehyde (MDA) concentration, a reduction in alpha-tocopherol concentration, a reduction in paraoxonase (PON) activity, an increase in glutathione peroxidase (GSH-Px), and glutathione reductase (GSSG-R) activity. Amlodipine increased PON and GSH-Px, but decreased GSSG-R activity and alpha-tocopherol concentration. Captopril decreased MDA concentration and the activity of both GSH-Px and GSSG-R, but increased alpha-tocopherol concentration and PON activity. Bezafibrate increased alpha-tocopherol concentration and PON activity, but decreased the activity of GSSG-R. Animals with fatty liver exhibit an increase in peroxidative stress but also a defect in anti-oxidative pathways. Drugs administered to treat hypertension and hypertriglyceridemia could lead to a variety of changes in the hepatic oxidative, anti-oxidative milieu.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17710547     DOI: 10.1007/s10620-007-9911-4

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  56 in total

1.  Control of oxidative stress and reduction in biochemical markers by Vitamin E treatment in patients with nonalcoholic steatohepatitis: a pilot study.

Authors:  Miwa Kawanaka; Sabina Mahmood; Gouichi Niiyama; Akiyoshi Izumi; Ayumi Kamei; Hideji Ikeda; Mitsuhiko Suehiro; Kazumi Togawa; Takayo Sasagawa; Misako Okita; Hajime Nakamura; Junji Yodoi; Gotaro Yamada
Journal:  Hepatol Res       Date:  2004-05       Impact factor: 4.288

2.  Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis.

Authors:  J R Jonsson; A D Clouston; Y Ando; L I Kelemen; M J Horn; M D Adamson; D M Purdie; E E Powell
Journal:  Gastroenterology       Date:  2001-07       Impact factor: 22.682

3.  Hypolipidemic drugs reduce lipoprotein susceptibility to undergo lipid peroxidation: in vitro and ex vivo studies.

Authors:  R Hoffman; G J Brook; M Aviram
Journal:  Atherosclerosis       Date:  1992-03       Impact factor: 5.162

4.  Non-alcoholic fatty liver disease in an area of southern Italy: main clinical, histological, and pathophysiological aspects.

Authors:  C Loguercio; V De Girolamo; I de Sio; C Tuccillo; A Ascione; F Baldi; G Budillon; L Cimino; A Di Carlo; M P Di Marino; F Morisco; F Picciotto; L Terracciano; R Vecchione; V Verde; C Del Vecchio Blanco
Journal:  J Hepatol       Date:  2001-11       Impact factor: 25.083

5.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome.

Authors:  Giulio Marchesini; Elisabetta Bugianesi; Gabriele Forlani; Fernanda Cerrelli; Marco Lenzi; Rita Manini; Stefania Natale; Ester Vanni; Nicola Villanova; Nazario Melchionda; Mario Rizzetto
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

6.  Antioxidant properties of calcium antagonists related to membrane biophysical interactions.

Authors:  R P Mason; I T Mak; M W Trumbore; P E Mason
Journal:  Am J Cardiol       Date:  1999-08-19       Impact factor: 2.778

7.  Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation.

Authors:  M D Weltman; G C Farrell; C Liddle
Journal:  Gastroenterology       Date:  1996-12       Impact factor: 22.682

8.  Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis.

Authors:  Jacob George; Natasha Pera; Nghi Phung; Isabelle Leclercq; Jing Yun Hou; Geoffrey Farrell
Journal:  J Hepatol       Date:  2003-11       Impact factor: 25.083

Review 9.  The ins and outs of mitochondrial dysfunction in NASH.

Authors:  B Fromenty; M A Robin; A Igoudjil; A Mansouri; D Pessayre
Journal:  Diabetes Metab       Date:  2004-04       Impact factor: 6.041

10.  Vitamin E dietary supplementation inhibits transforming growth factor beta 1 gene expression in the rat liver.

Authors:  M Parola; R Muraca; I Dianzani; G Barrera; G Leonarduzzi; P Bendinelli; R Piccoletti; G Poli
Journal:  FEBS Lett       Date:  1992-08-24       Impact factor: 4.124

View more
  2 in total

1.  PPARs in Regulation of Paraoxonases: Control of Oxidative Stress and Inflammation Pathways.

Authors:  Jordi Camps; Anabel García-Heredia; Anna Rull; Carlos Alonso-Villaverde; Gerard Aragonès; Raúl Beltrán-Debón; Esther Rodríguez-Gallego; Jorge Joven
Journal:  PPAR Res       Date:  2012-01-24       Impact factor: 4.964

2.  Bone marrow and nonbone marrow Toll like receptor 4 regulate acute hepatic injury induced by endotoxemia.

Authors:  Edith Hochhauser; Orna Avlas; Reut Fallach; Larissa Bachmetov; Romy Zemel; Orit Pappo; Asher Shainberg; Ziv Ben Ari
Journal:  PLoS One       Date:  2013-08-15       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.